The FDA has notified healthcare professionals and consumers that Insight Pharmaceuticals has recalled one lot of Nostrilla Nasal Decongestant (Oxymetazoline HCl nasal spray) because it may contain the bacteria Burkholderia cepacia. An internal investigation determined the potential presence of a microbial contaminant that exceeds the product specifications. This contaminant has been found sporadically throughout lot #11G075, UPC Code 6373673005.
Patients who have the affected product in their possession should stop using it immediately and contact their healthcare provider if they experience any adverse effects related to its use.
For more information visit www.fda.gov/Safety/Recalls/ucm276721.htm.